Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XcelerateXCRT Debt-to-EBITDA is -16.76 as of Sep. 2025. The stock has 4 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Xcelerate ranks worse than 207468.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Xcelerate's Debt-to-EBITDA or its related term are showing as below:
XCRT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.57 Med: 0.91 Max: 20.94
Current: -11.57
During the past 7 years, the highest Debt-to-EBITDA Ratio of Xcelerate was 20.94. The lowest was -11.57. And the median was 0.91.
XCRT's Debt-to-EBITDA is ranked worse than 100% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.2
vs XCRT: -11.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Xcelerate Debt-to-EBITDA Related Terms
Xcelerate Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Xcelerate's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCRT vs VLXC, RHEP, BICX: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Xcelerate's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xcelerate Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Xcelerate's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xcelerate's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.
Xcelerate (XCRT) has a Debt-to-EBITDA of -16.76 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Xcelerate. According to the industry distribution chart, Xcelerate ranks #999999 out of 482 companies in the Healthcare Providers & Services industry.
Is Xcelerate's Debt-to-EBITDA too high?
Xcelerate's current Debt-to-EBITDA is -16.76. Based on the distribution chart, Xcelerate ranks #999999 out of 482 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Xcelerate's Debt-to-EBITDA compare to VLXC and RHEP?
According to the Healthcare Providers & Services industry distribution chart, Xcelerate ranks #999999 out of 482 companies for Debt-to-EBITDA. This places Xcelerate in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Xcelerate. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xcelerate's current Debt-to-EBITDA is -16.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xcelerate stock overvalued right now?
Xcelerate (XCRT) has a current Debt-to-EBITDA of -16.76. The current Debt-to-EBITDA is -16.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Xcelerate (XCRT), the current Debt-to-EBITDA is -16.76 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xcelerate Inc is a healthcare services and products company engaged in three separate but related businesses within the medical, health, and wellness sectors. It is focused on the development of medical technology and the provision of virtual health services to help patients in developing countries meet their medical needs by extending the reach of physicians through technology. The company is also involved in the formulation, packaging, and marketing of consumer health and beauty, clinically tested skin and hair care products, and owns and licenses the rights to various forms of medical equipment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCRT has been successfully added to your 
